Your browser doesn't support javascript.
loading
CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions.
Herrera-Pariente, Cristina; Bonjoch, Laia; Muñoz, Jenifer; Fernàndez, Guerau; Soares de Lima, Yasmin; Mahmood, Romesa; Cuatrecasas, Miriam; Ocaña, Teresa; Lopez-Prades, Sandra; Llargués-Sistac, Gemma; Domínguez-Rovira, Xavier; Llach, Joan; Luzko, Irina; Díaz-Gay, Marcos; Lazaro, Conxi; Brunet, Joan; Castillo-Manzano, Carmen; García-González, María Asunción; Lanas, Angel; Carrillo, Marta; Hernández San Gil, Raquel; Quintero, Enrique; Sala, Nuria; Llort, Gemma; Aguilera, Lara; Carot, Laura; Diez-Redondo, Pilar; Jover, Rodrigo; Ramon Y Cajal, Teresa; Cubiella, Joaquín; Castells, Antoni; Balaguer, Francesc; Bujanda, Luis; Castellví-Bel, Sergi; Moreira, Leticia.
Afiliación
  • Herrera-Pariente C; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Bonjoch L; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Muñoz J; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Fernàndez G; Hospital Sant Joan de Déu, CIBERER, 08950, Barcelona, Spain.
  • Soares de Lima Y; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Mahmood R; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Cuatrecasas M; Pathology, Hospital Clínic, FRCB-IDIBAPS, CIBEREHD, 08036, Barcelona, Spain.
  • Ocaña T; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Lopez-Prades S; Pathology, Hospital Clínic, FRCB-IDIBAPS, CIBEREHD, 08036, Barcelona, Spain.
  • Llargués-Sistac G; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Domínguez-Rovira X; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Llach J; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Luzko I; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Díaz-Gay M; Department of Cellular and Molecular Medicine and Department of Bioengineering and Moores Cancer Center, UC San Diego, La Jolla, San Diego, CA, 92093, USA.
  • Lazaro C; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, 08908, Barcelona, Spain.
  • Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, 08908, Barcelona, Spain.
  • Castillo-Manzano C; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, 17190, Girona, Spain.
  • García-González MA; Hereditary Cancer Program, Catalan Institute of Oncology, 08916, Badalona, Spain.
  • Lanas A; Instituto de Investigación Sanitaria Aragón, Instituto Aragonés de Ciencias de La Salud, CIBEREHD, 50009, Zaragoza, Spain.
  • Carrillo M; Instituto de Investigación Sanitaria Aragón, Instituto Aragonés de Ciencias de La Salud, CIBEREHD, 50009, Zaragoza, Spain.
  • Hernández San Gil R; Gastroenterology, Hospital Clínico Universitario de Zaragoza, Instituto de Investigación Sanitaria Aragón, Universidad de Zaragoza, CIBEREHD, 50009, Zaragoza, Spain.
  • Quintero E; Gastroenterology, Centro de Investigación Biomédica de Canarias (CIBICAN), Hospital Universitario de Canarias, Instituto Universitario de Tecnologías Biomédicas (ITB), Universidad de La Laguna, 38320, Santa Cruz de Tenerife, Spain.
  • Sala N; Department of Medical Oncology, Hospital Universitario de Canarias, 38320, Tenerife, Spain.
  • Llort G; Gastroenterology, Centro de Investigación Biomédica de Canarias (CIBICAN), Hospital Universitario de Canarias, Instituto Universitario de Tecnologías Biomédicas (ITB), Universidad de La Laguna, 38320, Santa Cruz de Tenerife, Spain.
  • Aguilera L; Unit of Nutrition and Cancer, Translational Research Laboratory, Catalan Institute of Oncology (ICO) and Bellvitge Biomedical Research Institute (IDIBELL), 08908, Barcelona, Spain.
  • Carot L; Medical Oncology, Parc Taulí University Hospital, 08208, Sabadell, Spain.
  • Diez-Redondo P; Gastroenterology, Vall d'Hebron Research Institute, 08035, Barcelona, Spain.
  • Jover R; Gastroenterology, Hospital del Mar, 08003, Barcelona, Spain.
  • Ramon Y Cajal T; Hospital Universitario Río Hortega, 47012, Valladolid, Spain.
  • Cubiella J; Gastroenterology, Departamento de Medicina Clínica, Hospital General Universitario Dr. Balmis, Instituto de Investigación Sanitaria ISABIAL, Universidad Miguel Hernández, 03010, Alicante, Spain.
  • Castells A; Medical Oncology, Santa Creu I Sant Pau Hospital, 08041, Barcelona, Spain.
  • Balaguer F; Gastroenterology, Complexo Hospitalario de Ourense, CIBEREHD, 32005, Ourense, Spain.
  • Bujanda L; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Castellví-Bel S; Gastroenterology, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer (FRCB-IDIBAPS), CIBEREHD, Universitat de Barcelona, Hospital Clínic, Villarroel 170, 08036, Barcelona, Spain.
  • Moreira L; Department of Hepatology and Gastroenterology, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Biodonostia Health Research Institute - Donostia University Hospital, Universidad del País Vasco (UPV/EHU), 20014, San Sebastián, Spain.
Gastric Cancer ; 27(4): 747-759, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38796558
ABSTRACT

BACKGROUND:

CDH1 and CTNNA1 remain as the main genes for hereditary gastric cancer. However, they only explain a small fraction of gastric cancer cases with suspected inherited basis. In this study, we aimed to identify new hereditary genes for early-onset gastric cancer patients (EOGC; < 50 years old).

METHODS:

After germline exome sequencing in 20 EOGC patients and replication of relevant findings by gene-panel sequencing in an independent cohort of 152 patients, CTNND1 stood out as an interesting candidate gene, since its protein product (p120ctn) directly interacts with E-cadherin. We proceeded with functional characterization by generating two knockout CTNND1 cellular models by gene editing and introducing the detected genetic variants using a lentiviral delivery system. We assessed ß-catenin and E-cadherin levels, cell detachment, as well as E-cadherin localization and cell-to-cell interaction by spheroid modeling.

RESULTS:

Three CTNND1 germline variants [c.28_29delinsCT, p.(Ala10Leu); c.1105C > T, p.(Pro369Ser); c.1537A > G, p.(Asn513Asp)] were identified in our EOGC cohorts. Cells encoding CTNND1 variants displayed altered E-cadherin levels and intercellular interactions. In addition, the p.(Pro369Ser) variant, located in a key region in the E-cadherin/p120ctn binding domain, showed E-cadherin mislocalization.

CONCLUSIONS:

Defects in CTNND1 could be involved in germline predisposition to gastric cancer by altering E-cadherin and, consequently, cell-to-cell interactions. In the present study, CTNND1 germline variants explained 2% (3/172) of the cases, although further studies in larger external cohorts are needed.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Cadherinas / Mutación de Línea Germinal / Predisposición Genética a la Enfermedad / Cateninas / Catenina delta Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Gastric Cancer Asunto de la revista: GASTROENTEROLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Cadherinas / Mutación de Línea Germinal / Predisposición Genética a la Enfermedad / Cateninas / Catenina delta Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Gastric Cancer Asunto de la revista: GASTROENTEROLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: España